Longitudinal analysis of circulating dsDNA at days 0, +14, +30, +60, and +100. (A) Levels of dsDNA were elevated at day +14 following HSCT for the entire cohort of patients. Median levels of dsDNA for each time point are included in the table below the figure, including range and interquartile range. (B-E) When broken down by development of GVHD and TA-TMA, the day +14 spike in levels of dsDNA persisted for each group. (F) Day +14 levels above the median for the cohort were associated with increased risk of future development of TA-TMA compared with levels less than the median (P = .01).